J. P. Morgan

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of QuidelOrtho Corporation - QDEL

Retrieved on:

Thursday, March 7, 2024

J. P. Morgan, LLP, News, Pomerantz, QuidelOrtho, Cryptocurrency

NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of QuidelOrtho Corporation (“QuidelOrtho” or the “Company”) (NASDAQ: QDEL).

Key Points:

NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of QuidelOrtho Corporation (“QuidelOrtho” or the “Company”) (NASDAQ: QDEL).
The investigation concerns whether QuidelOrtho and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
On February 13, 2024, QuidelOrtho issued a press release announcing its fourth quarter and full-year 2023 financial results.
Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of iRhythm

Retrieved on:

Thursday, March 7, 2024

Zio, Court, Boston Scientific, Marketing, FDA, J. P. Morgan, Advertising, Growth, IRTC, DOJ, Patient, LLP, Justice, Subpoena duces tecum, Pharmaceutical industry

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.

Key Points:

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.
The firm has recovered hundreds of millions of dollars for investors since its founding in 1995.
As a result of these misrepresentations, the price of iRhythm common stock traded at artificially inflated prices throughout the Class Period.
Faruqi & Faruqi, LLP also encourages anyone with information regarding iRhythm’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against iRhythm, Hut 8, Xponential, and Amplitude and Encourages Investors to Contact the Firm

Retrieved on:

Thursday, March 7, 2024

The Company’s principal product is a monitoring patch that provides electrocardiogram (“ECG”) monitoring for up to 14 days, called Zio XT.

Key Points:

The Company’s principal product is a monitoring patch that provides electrocardiogram (“ECG”) monitoring for up to 14 days, called Zio XT.
The Zio XT is intended for non-critical patients, as it does not provide real-time reporting.
These types of heart monitors that are approved for high-risk patients and provide near real-time alerts are also referred to as “real-time” monitors.
As a result of these misrepresentations, the price of iRhythm common stock traded at artificially inflated prices throughout the Class Period.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against iRhythm, Hut 8, Xponential, and Amplitude and Encourages Investors to Contact the Firm

Retrieved on:

Sunday, March 3, 2024

The Company’s principal product is a monitoring patch that provides electrocardiogram (“ECG”) monitoring for up to 14 days, called Zio XT.

Key Points:

The Company’s principal product is a monitoring patch that provides electrocardiogram (“ECG”) monitoring for up to 14 days, called Zio XT.
The Zio XT is intended for non-critical patients, as it does not provide real-time reporting.
These types of heart monitors that are approved for high-risk patients and provide near real-time alerts are also referred to as “real-time” monitors.
As a result of these misrepresentations, the price of iRhythm common stock traded at artificially inflated prices throughout the Class Period.

IRHYTHM INVESTOR ALERT: Kirby McInerney LLP Notifies iRhythm Technologies, Inc. (IRTC) Investors of Upcoming Lead Plaintiff Deadline in Class Action Lawsuit

Retrieved on:

Friday, March 1, 2024

Zio, Court, Boston Scientific, Marketing, FDA, J. P. Morgan, News, Growth, IRTC, DOJ, Patient, LLP, Justice, Subpoena duces tecum, Pharmaceutical industry

Investors have until April 8, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points:

Investors have until April 8, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
The lawsuit alleges that, throughout the Class Period, iRhythm failed to disclose serious issues with its Zio AT heart monitor to the FDA, patients, or investors.
As a result of these representations, the price of iRhythm common stock traded at artificially inflated prices throughout the Class Period.
Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation.

Athene Prices $500 Million Investment Grade Junior Subordinated Debentures Offering

Retrieved on:

Friday, March 1, 2024

Morgan Stanley, J.P. Morgan & Co., Prospectus, J. P. Morgan, RBC Capital Markets, Sale, Exercise, Wells Fargo, BofA Securities, Security (finance), Goldman Sachs, Insurance

WEST DES MOINES, Iowa, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Athene Holding Ltd. (“Athene”) today announced it has agreed to sell $500 million aggregate principal amount of 7.250% fixed-rate reset junior subordinated debentures due 2064 and to grant the underwriters an option, exercisable for 30 days, to purchase up to an additional $75 million aggregate principal amount of debentures solely to cover over-allotments.

Key Points:

WEST DES MOINES, Iowa, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Athene Holding Ltd. (“Athene”) today announced it has agreed to sell $500 million aggregate principal amount of 7.250% fixed-rate reset junior subordinated debentures due 2064 and to grant the underwriters an option, exercisable for 30 days, to purchase up to an additional $75 million aggregate principal amount of debentures solely to cover over-allotments.
The offering is expected to close on March 7, 2024, subject to satisfaction of customary closing conditions.
Wells Fargo Securities, BofA Securities, J.P. Morgan and Morgan Stanley are acting as joint book-running managers for the offering.
The debentures are being offered pursuant to an effective shelf registration statement that has previously been filed with the Securities and Exchange Commission (the “SEC”).

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of iRhythm

Retrieved on:

Friday, March 1, 2024

Zio, Court, Boston Scientific, Marketing, FDA, J. P. Morgan, Advertising, Growth, IRTC, DOJ, Patient, LLP, Justice, Subpoena duces tecum, Pharmaceutical industry

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.

Key Points:

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.
The firm has recovered hundreds of millions of dollars for investors since its founding in 1995.
As a result of these misrepresentations, the price of iRhythm common stock traded at artificially inflated prices throughout the Class Period.
Faruqi & Faruqi, LLP also encourages anyone with information regarding iRhythm’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Colliers International Group Inc. Completes US$300 Million Bought Deal Public Offering of Equity

Retrieved on:

Wednesday, February 28, 2024

TORONTO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Colliers International Group Inc. (TSX and NASDAQ: CIGI) (“Colliers” or the “Company”) is pleased to report that it has closed its previously announced bought deal public offering of 2,479,500 subordinate voting shares (the “Subordinate Voting Shares”), at a price of US$121.00 per Subordinate Voting Share for gross proceeds of US$300.0 million (the “Offering”) with a syndicate of underwriters led by BMO Capital Markets and J.P. Morgan as joint bookrunners, and including Mizuho, National Bank Financial, RBC Capital Markets, Scotiabank, Merrill Lynch, BTIG, LLC, CIBC Capital Markets, Goldman Sachs, Raymond James, TD Securities, Wells Fargo and Stifel Nicolaus (the “Underwriters”).

Key Points:

TORONTO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Colliers International Group Inc. (TSX and NASDAQ: CIGI) (“Colliers” or the “Company”) is pleased to report that it has closed its previously announced bought deal public offering of 2,479,500 subordinate voting shares (the “Subordinate Voting Shares”), at a price of US$121.00 per Subordinate Voting Share for gross proceeds of US$300.0 million (the “Offering”) with a syndicate of underwriters led by BMO Capital Markets and J.P. Morgan as joint bookrunners, and including Mizuho, National Bank Financial, RBC Capital Markets, Scotiabank, Merrill Lynch, BTIG, LLC, CIBC Capital Markets, Goldman Sachs, Raymond James, TD Securities, Wells Fargo and Stifel Nicolaus (the “Underwriters”).
Colliers has granted the Underwriters an option, exercisable at the offering price for a period of 30 days following the closing of the Offering, to purchase up to an additional 15% of the Offering to cover over-allotments, if any.
The net proceeds of the Offering will be used to repay balances outstanding on the Company’s credit facility and are intended to create additional capacity to fund potential future acquisition opportunities and growth initiatives, and for general corporate purposes.
No securities regulatory authority has either approved or disapproved of the contents of this news release.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of QuidelOrtho Corporation - QDEL

Retrieved on:

Wednesday, February 28, 2024

J. P. Morgan, LLP, News, Pomerantz, QuidelOrtho, Cryptocurrency

NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of QuidelOrtho Corporation (“QuidelOrtho” or the “Company”) (NASDAQ: QDEL).

Key Points:

NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of QuidelOrtho Corporation (“QuidelOrtho” or the “Company”) (NASDAQ: QDEL).
The investigation concerns whether QuidelOrtho and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
On February 13, 2024, QuidelOrtho issued a press release announcing its fourth quarter and full-year 2023 financial results.
Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

G1 Therapeutics Provides Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights

Retrieved on:

Wednesday, February 28, 2024

G1 Therapeutics, Breast cancer, Carboplatin, Research, PIN, SCLC, Telephone, Update, J. P. Morgan, DMC, Food, Growth, SACT, G1, Trilaciclib, Hospital, ADC, OS, Conjugation, GAAP, Event, Therapy, Webcast, Patent, Patient, Acceleration, Clinical trial, Survival, Oncology, ITT, Pharmaceutical industry

G1 recognized total revenues of $14.9 million and $82.5 million for the fourth quarter and full year of 2023, respectively.

Key Points:

G1 recognized total revenues of $14.9 million and $82.5 million for the fourth quarter and full year of 2023, respectively.
Operating expenses for the fourth quarter of 2023 were $23.8 million, compared to $41.1 million for the fourth quarter of 2022.
Research and development (R&D) expenses for the fourth quarter of 2023 were $7.4 million, compared to $16.6 million for the fourth quarter of 2022.
The net loss for the fourth quarter of 2023 was $10.9 million, compared to $33.6 million for the fourth quarter of 2022.